SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Metlife Inc. – ‘8-K’ for 7/7/22 – ‘EX-5.1’

On:  Monday, 7/11/22, at 4:25pm ET   ·   For:  7/7/22   ·   Accession #:  1193125-22-191281   ·   File #:  1-15787

Previous ‘8-K’:  ‘8-K’ on 6/24/22 for 6/21/22   ·   Next:  ‘8-K’ on / for 8/3/22   ·   Latest:  ‘8-K’ on / for 5/1/24   ·   7 References:   

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 7/11/22  Metlife Inc.                      8-K:2,8,9   7/07/22   15:693K                                   Donnelley … Solutions/FA

Current Report   —   Form 8-K

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                      HTML     34K 
 2: EX-1.1      Underwriting Agreement or Conflict Minerals Report  HTML    181K 
 3: EX-1.2      Underwriting Agreement or Conflict Minerals Report  HTML     33K 
 4: EX-4.1      Instrument Defining the Rights of Security Holders  HTML     74K 
 5: EX-5.1      Opinion of Counsel re: Legality                     HTML     16K 
10: R1          Document and Entity Information                     HTML     56K 
13: XML         IDEA XML File -- Filing Summary                      XML     13K 
11: XML         XBRL Instance -- d375895d8k_htm                      XML     24K 
12: EXCEL       IDEA Workbook of Financial Reports                  XLSX      6K 
 7: EX-101.DEF  XBRL Definitions -- met-20220707_def                 XML     43K 
 8: EX-101.LAB  XBRL Labels -- met-20220707_lab                      XML     70K 
 9: EX-101.PRE  XBRL Presentations -- met-20220707_pre               XML     45K 
 6: EX-101.SCH  XBRL Schema -- met-20220707                          XSD     15K 
14: JSON        XBRL Instance as JSON Data -- MetaLinks               14±    22K 
15: ZIP         XBRL Zipped Folder -- 0001193125-22-191281-xbrl      Zip     75K 


‘EX-5.1’   —   Opinion of Counsel re: Legality


This Exhibit is an HTML Document rendered as filed.  [ Alternative Formats ]



  EX-5.1  

Exhibit 5.1

 

LOGO           

787 Seventh Avenue
New York, NY 10019-6099
Tel: 212 728 8000

Fax: 212 728 8111

July 11, 2022    

MetLife, Inc.

200 Park Avenue

New York, NY 10166

 

  RE:

METLIFE, INC. - UNDERWRITTEN PUBLIC OFFERING OF SENIOR NOTES

Ladies and Gentlemen:

We have acted as special counsel to MetLife, Inc., a Delaware corporation (the “Company”), in connection with the issuance and sale by the Company of $1,000,000,000 in aggregate principal amount of its 5.000% Senior Notes due 2052 (the “Senior Notes”), pursuant to the Underwriting Agreement, dated July 7, 2022 (the “Underwriting Agreement”), among the Company and the representatives (the “Representatives”) of the underwriters (the “Underwriters”) listed on Schedule I to the Pricing Agreement, dated July 7, 2022 (the “Pricing Agreement”), among the Company and the Representatives. Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to such terms in the Underwriting Agreement.

In the above capacity, we have reviewed: (a) the registration statement on Form S-3 (File No. 333-234761) filed by the Company with the Securities and Exchange Commission (the “Commission”) pursuant to the Securities Act of 1933, as amended (the “Securities Act”), which automatically became effective under the Securities Act on November 18, 2019, allowing for delayed offerings pursuant to Rule 415 of the General Rules and Regulations under the Securities Act (the “Rules and Regulations”), including the documents incorporated by reference therein (the “Registration Statement”); (b) the prospectus, dated November 18, 2019 (the “Base Prospectus”), filed as part of the Registration Statement; (c) the preliminary prospectus supplement, dated July 7, 2022, relating to the Senior Notes, in the form filed by the Company with the Commission on July 7, 2022 pursuant to Rule 424(b) of the Rules and Regulations; (d) the prospectus supplement, dated July 7, 2022 (together with the Base Prospectus, the “Prospectus”), relating to the Senior Notes, in the form filed by the Company with the Commission on July 8, 2022 pursuant to Rule 424(b) of the Rules and Regulations; (e) the Issuer Free Writing Prospectus containing the final pricing terms of the Senior Notes filed by the Company with the Commission on July 7, 2022; (f) an executed copy of the Underwriting Agreement; (g) an executed copy of the Pricing Agreement; (h) an executed copy of the Indenture, dated as of November 9, 2001 (the “Senior Indenture”), between the Company and The Bank of New York Mellon Trust Company, N.A. (as successor to J.P. Morgan Trust

BRUSSELS    CHICAGO    FRANKFURT     HOUSTON    LONDON    LOS   ANGELES     MILAN

NEW   YORK     PALO   ALTO     PARIS     ROME     SAN   FRANCISCO     WASHINGTON


MetLife, Inc.

July 11, 2022

Page 2

Company National Association (as successor to Bank One Trust Company, N.A.)), as trustee (the “Trustee”); (i) an executed copy of the Thirty-Sixth Supplemental Indenture relating to the Senior Notes, dated as of July 11, 2022 (the “Supplemental Indenture”), each between the Company and the Trustee; (j) copies of the certificates executed by the Company representing the Senior Notes; and (k) such other records of the corporate proceedings of the Company as we have deemed necessary as the basis for the opinions expressed herein.

We have also examined, have relied as to matters of fact upon and have assumed the accuracy of originals or copies certified, or otherwise identified to our satisfaction, of such records, agreements, documents and other instruments and such representations, statements and certificates or comparable documents of or from public officials and officers and representatives of the Company and of representations of such persons whom we have deemed appropriate, and have made such other investigations as we have deemed relevant and necessary as a basis for the opinions hereinafter set forth. In such examination, and in connection with our review of all such documents, including the documents referred to in clauses (a) through (k) of the preceding paragraph, we have assumed the genuineness of all signatures, the authenticity of all documents submitted to us as originals, the conformity to original documents of all documents submitted to us as copies and the authenticity of the originals of such latter documents.

With your permission, for purposes of the opinion expressed herein, we have assumed that the Trustee has the power and authority to authenticate the certificates representing the Senior Notes.

Based upon and subject to the foregoing, and subject to the further limitations, qualifications and assumptions stated herein, we are of the opinion that the issuance and sale of the Senior Notes have been duly authorized by the Company, each certificate representing the Senior Notes has been duly executed and delivered by the Company, and when each certificate representing the Senior Notes has been authenticated and delivered by the Trustee in accordance with the terms of the Senior Indenture and the Supplemental Indenture and the Senior Notes have been delivered to the Underwriters against payment therefor in accordance with the terms of the Underwriting Agreement, the Pricing Agreement, the Senior Indenture and the Supplemental Indenture, the Senior Notes will constitute valid and legally binding obligations of the Company, entitled to the benefits of the Senior Indenture and the Supplemental Indenture, and will be enforceable against the Company in accordance with their terms, subject to (i) bankruptcy, insolvency, reorganization, moratorium, fraudulent transfer and other similar laws now or hereafter in effect relating to or affecting creditors’ rights generally; and (ii) general principles of equity (regardless of whether such principles are considered in a proceeding at law or in equity).

We express no opinion as to the effect of any federal or state laws regarding fraudulent transfers or conveyances. We express no opinion as to the laws of any jurisdiction other than the laws of the State of New York, the General Corporation Law of the State of Delaware and the federal laws of the United States. In particular (and without limiting the generality of the foregoing), we express no opinion concerning the effect, if any, of any law of any jurisdiction (except the State of New York) in which any holder of any Senior Notes is located that limits the rate of interest that such holder may charge or collect. Furthermore, we express no opinion as to: (i) whether a United States federal court would accept jurisdiction in any dispute, action, suit or proceeding arising out of or relating to the Senior Notes or the Indenture or the transactions contemplated thereby; and (ii) any waiver of inconvenient forum.


MetLife, Inc.

July 11, 2022

Page 3

This opinion letter is rendered as of the date hereof based upon the facts and law in existence on the date hereof. We assume no obligation to update or supplement this opinion letter to reflect any circumstances that may come to our attention after the date hereof with respect to the opinion and statements set forth above, including any changes in applicable law that may occur after the date hereof.

We consent to the filing of this opinion letter as an exhibit to the Company’s Current Report on Form 8-K to be filed in connection with the issuance and sale of the Senior Notes, which will be incorporated by reference into the Registration Statement and the Prospectus and to the use of our name under the caption “Legal Opinions” contained in the Prospectus. In giving our consent, we do not thereby concede that we come within the category of persons whose consent is required by the Securities Act or the Rules and Regulations.

 

Very truly yours,
/s/ Willkie Farr & Gallagher LLP

Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘8-K’ Filing    Date    Other Filings
Filed on:7/11/22
7/8/22424B2
For Period end:7/7/22424B2,  FWP
11/18/19S-3ASR
11/9/018-K
 List all Filings 


7 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 3/04/24  MetLife, Inc.                     424B2                  2:980K                                   Donnelley … Solutions/FA
 2/26/24  MetLife, Inc.                     424B2                  1:742K                                   Donnelley … Solutions/FA
 7/11/23  MetLife, Inc.                     424B2                  2:883K                                   Donnelley … Solutions/FA
 7/10/23  MetLife, Inc.                     424B2                  1:710K                                   Donnelley … Solutions/FA
 1/05/23  MetLife, Inc.                     424B2                  2:879K                                   Donnelley … Solutions/FA
 1/03/23  MetLife, Inc.                     424B2                  1:711K                                   Donnelley … Solutions/FA
11/17/22  MetLife, Inc.                     S-3ASR     11/17/22    6:530K                                   Donnelley … Solutions/FA
Top
Filing Submission 0001193125-22-191281   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Tue., May 14, 7:33:48.1am ET